DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vitrase (Hyaluronidase, Ovine) - Summary

 
 



VITRASE SUMMARY

VITRASEĀ is a preparation of purified ovine testicular hyaluronidase, a protein enzyme. The exact chemical structure of this enzyme is unknown.
VITRASEĀ (hyaluronidase injection) is supplied as a sterile, non-preserved, colorless solution with a pH of 6.4 to 7.2. Each mL contains 200 USP units of ovine hyaluronidase with 0.93 mg lactose, 0.36 mg potassium phosphate dibasic, 0.23 mg potassium phosphate monobasic, and 9.0 mg sodium chloride.

Subcutaneous Fluid Administration

VITRASE (hyaluronidase injection) is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.

Dispersion and Absorption of Injected Drugs

VITRASE is indicated as an adjuvant to increase dispersion and absorption of other injected drugs.

Subcutaneous Urography

VITRASE is indicated as an adjuvant in subcutaneous urography for improving resorption of radiopaque agents.


See all Vitrase indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Vitrase (Hyaluronidase)

Facing, Not Fearing, Uncertainty in Diagnostic Testing
Source: Medscape Nurses Headlines [2017.09.12]
We must acknowledge the subjectivity inherent in diagnosis and remember that diagnostic tests are tools that should not overrule clinical judgment.
Medscape Nurses

New Headache Diagnostic Criteria Will Coordinate with ICD-11
Source: Medscape Anesthesiology Headlines [2017.09.11]
The new International Classification of Headache Disorders-3, now under development, will allow more consistent diagnoses and better clinical trials, as well as coordinating with ICD-11.
Medscape Medical News

New Diagnostic Codes Lessen Stigma for Transgender People
Source: Medscape NeurologyHeadlines [2017.09.11]
Changes in the DSM-5 and ICD-11 are meant to improve accuracy and reduce stigma but retain access to care, says Dr Jack Drescher.
Medscape Psychiatry

Diagnostic Mammograms Find More Cancers, and More False-Positives
Source: MedicineNet Mammogram Specialty [2017.02.28]
Title: Diagnostic Mammograms Find More Cancers, and More False-Positives
Category: Health News
Created: 2/28/2017 12:00:00 AM
Last Editorial Review: 2/28/2017 12:00:00 AM

Guidance Issued on PET Imaging in Diagnosing Cardiac Sarcoidosis
Source: MedPage Today Radiology [2017.08.19]
(MedPage Today) -- ASNC, SNMMI release recommendations for difficult diagnostic challenge

more news >>

Published Studies Related to Vitrase (Hyaluronidase)

Adjuvant hyaluronidase to epidural steroid improves the quality of analgesia in failed back surgery syndrome: a prospective randomized clinical trial. [2014]
STUDY DESIGN: Prospective randomized trial... CONCLUSION: We conclude that adding hyaluronidase to the epidural injectate was

Predicting response of vitreous hemorrhage after intravitreous injection of highly purified ovine hyaluronidase (Vitrase) in patients with diabetes. [2008.10]
PURPOSE: To develop a predictive model for patients with diabetes who are most likely to have vitreous hemorrhage clearing by 3 months after a single, intravitreous injection of highly purified, preservative-free, ovine hyaluronidase (Vitrase; ISTA Pharmaceuticals, Inc., Irvine, CA)...

Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. [2005.10]
PURPOSE: To evaluate the safety of intravitreous ovine hyaluronidase for the management of vitreous hemorrhage. DESIGN: Two prospective, randomized, placebo-controlled, double-masked studies. Pooled efficacy data are presented in a companion article in this issue of The Journal... CONCLUSIONS: No serious safety issues were reported after a single intravitreous injection of ovine hyaluronidase. RD incidence was not statistically different between groups. Iritis manifesting as an acute self limited inflammation was the most common adverse event, occurred in a dose response fashion, but was not noted to result in a serious adverse event in any hyaluronidase treated eye.

Hyaluronidase for reducing perineal trauma. [2014]
CONCLUSIONS: Perineal HAase injection during second stage of labour had

Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. [2014]
ondansetron monotherapy in healthy volunteers... CONCLUSIONS: Subcutaneous ondansetron + rHuPH20 was generally well-tolerated.

more studies >>

Clinical Trials Related to Vitrase (Hyaluronidase)

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage [Completed]

Evaluation of Vitrase as a Spreading Agent [Completed]
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) [Completed]
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) [Completed]
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment [Completed]
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.

more trials >>


Page last updated: 2017-09-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017